This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Hernandez Borrero L , Dicker DT , Santiago J , Sanders J , Tian X , Ahsan N , Lev A , Zhou L , El-Deiry WS
A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
Elife. 2021 Jul 29;10
PMID: 34324416 PMCID: PMC8321552
AbstractMutations in TP53 occur commonly in the majority of human tumors and confer aggressive tumor phenotypes, including metastasis and therapy resistance. CB002 and structural-analogs restore p53 signaling in tumors with mutant-p53 but we find that unlike other xanthines such as caffeine, pentoxifylline, and theophylline, they do not deregulate the G2 checkpoint. Novel CB002-analogs induce pro-apoptotic Noxa protein in an ATF3/4-dependent manner, whereas caffeine, pentoxifylline, and theophylline do not. By contrast to caffeine, CB002-analogs target an S-phase checkpoint associated with increased p-RPA/RPA2, p-ATR, decreased Cyclin A, p-histone H3 expression, and downregulation of essential proteins in DNA-synthesis and DNA-repair. CB002-analog #4 enhances cell death, and decreases Ki-67 in patient-derived tumor-organoids without toxicity to normal human cells. Preliminary in vivo studies demonstrate anti-tumor efficacy in mice. Thus, a novel class of anti-cancer drugs shows the activation of p53 pathway signaling in tumors with mutated p53, and targets an S-phase checkpoint.
Notes2050-084x Hernandez Borrero, Liz Orcid: 0000-0003-4249-5358 Dicker, David T Santiago, John Sanders, Jennifer Tian, Xiaobing Ahsan, Nagib Lev, Avital Zhou, Lanlan El-Deiry, Wafik S Orcid: 0000-0002-9577-8266 Minority Scholar Research Award/American Association for Cancer Research/ CA176289/NH/NIH HHS/United States Journal Article Elife. 2021 Jul 29;10:e70429. doi: 10.7554/eLife.70429.